Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OH2 + BS006 in advanced solid tumors
NCT07382531Phase 2Recruiting
- Sponsor
- Wuhan Binhui Biopharmaceutical Co., Ltd.
- Start
- Sep 2023
- Primary completion
- Dec 2027
- Modality
- Prophylactic Vaccines, Oncolytic Viruses, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BS-006 in Malignant Melanoma (MM), head and neck cancer (HNC), soft tissue sarcoma (STS) and 6 more, sponsored by Wuhan Binhui Biopharmaceutical Co., Ltd. Primary endpoints: Adverse Event, Serious Adverse Event and 2 more. Started Sep 2023; status: recruiting.
02
Drugs
BS-006
03
Conditions
Malignant Melanoma (MM)head and neck cancer (HNC)soft tissue sarcoma (STS)hepatocellular carcinoma (HCC)liver metastases
Beyond the preview
Go deeper on NCT07382531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07382531.